The stock of Gossamer Bio Inc. (NASDAQ:GOSS) decreased by -$0.01 on Tuesday to finish at $0.93, down -1.05 percent. The last five days have seen an average of 5,008,400 shares of common stock traded. 9 times new highs were reached in the current year, with a fall of -$1.2369. The average number of shares traded over the last 20 days was 2,465,250, while the average volume over the last 50 days totaled 2,474,332.
GOSS stock dropped -7.61% since last month. On 09/15/23, the company’s shares reached a one-month low of $0.8440. The stock touched a high of $13.83 on 02/02/23, after rallying from a low of $0.84 in 52 weeks. The price of GOSS stock has declined by -57.00% or -$1.2369 this year, reaching a new high 9 times. Still, the stock price is down -93.25% from the 52-week high.
Top 5 AI Stocks to Buy for 2023
The artificial intelligence (AI) revolution is already here. And it's about to change everything we know about everything.
According to Grand View Research, the global AI boom could grow from about $137 billion in 2022 to more than $1.81 trillion by 2030. And investors like you always want to get in on the hottest stocks of tomorrow. Here are five of the best ways to profit from the AI boom.
Click Here to Download the FREE Report.
Sponsored
Insider Transactions
GOSS stock investors should be aware that Gossamer Bio Inc. (GOSS) stock had its last reported insider trading activity 90 days ago on Jun 22. On Jun 22, Chief Medical Officer Aranda Richard sold 1,814 shares at $1.29 each. This transaction resulted in the insider making $2,340. On Apr 04, Giraudo Bryan added 55,000 shares at a price of US$1.02. After the transaction, the insider now owns 125,990 shares. President & CEO Hasnain Faheem had earlier bought 440,500 shares on Mar 22 for $1.14 a share. The transaction was completed for $503,580.
Financial Health
For the recent quarter, Gossamer Bio Inc.’s quick ratio was 4.30, while its current ratio was 4.30, indicating its ability to pay off its debt. Based on annual data, it had gross profit of $13.88 million and revenue of $218.59 million.
Investors will also look at the performance of the company’s management in order to determine the potential profitability of their investment. GOSS’s return on assets (ROA) during the last 12 months has been -82.90%.
Earnings Surprise
A lower net income was reported in the quarter under review than the previous quarter. EBITDA was -$46.32 million for the quarter. At the end of Gossamer Bio Inc.’s most recent quarter, its liabilities totaled 244.55 million, while its total debt was $219.16 million. Equity owned by shareholders amounts to $225.32 million.
Technical Picture
Here’s a quick look at Gossamer Bio Inc.’s (GOSS) price momentum from a technical perspective. As of 19 September, the RSI 9-day stood at 38.25%, suggesting the stock is Neutral, with a 51.83% historical volatility rate.
The stochastic %K and %D were 30.83% and 22.93% respectively, while the average true range (ATR) was 0.0787. Based on the 14-day stochastic reading of 31.15%, the RSI (14) reading is 37.87%. On the 9-day MACD Oscillator, the stock is at -0.0102, and the 14-day reading is at -0.0451.
Analyst Ratings
Gossamer Bio Inc. (NASDAQ: GOSS) was downgraded by UBS to a a Neutral rating in its latest research report. The stock was previously rated as a a Buy. Analysts have assigned Gossamer Bio Inc. (GOSS) an Overweight rating. GOSS is a stock that is recommended for selling by 1 brokerage firm, while 4 companies recommend holding. The stock is underweighted by 0 analysts. Among the analysts who rate the stock, 0 rates it overweight and 6 others recommend it as a buy.
What is GOSS’s price target for the next 12 months?
The current consensus forecast for the stock is between $1.25 and $15.00, with a median target price of $4.00. In analyzing these forecasts, the average price target given by analysts for Gossamer Bio Inc. (GOSS) is $5.31.
